Breaking News

Japan Approves Takeda's NDA for Cell-Cultured Flu Vaccine

April 2, 2014

Japan's Ministry of Health, Labor and Welfare has approved Takeda's NDA for cell-cultured flu vaccine, using Baxter International's technology.

This week, a number of news sources reported that Japan's Ministry of Health,Labor and Welfare has approved Takeda International's NDA for cell-cultured influenza vaccine. Pharmaceutical Business Review reported on April 1 that the vaccine will be made at a new facility at Takeda's Hikan manufacturing complex in Yamaguchi Prefecture.  The company will reportedly use technology that it licensed from Baxter International, and which the two companies have been jointly developing since 2010.  
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments